brivanib alaninate + cetuximab

Brivanib alaninate + cetuximab is a combination therapy investigated for the treatment of advanced and metastatic colorectal cancer (particularly KRAS wild-type), as well as other advanced gastrointestinal malignancies. Brivanib alaninate is an oral prodrug that converts to brivanib (BMS-540215), a small molecule dual tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR). Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The rationale for combining these agents is to simultaneously inhibit tumor angiogenesis and EGFR-mediated signaling pathways. Clinical trials have shown that while this combination can improve progression-free survival and objective response rates compared to cetuximab alone in chemotherapy-refractory metastatic colorectal cancer, it does not significantly improve overall survival and increases toxicity with worsened quality of life[1][2][3][4].

Brand names

Erbitux

Other names

brivanib + cetuximabcetuximab + brivanib alaninate